Table 1.
Clinical characteristics | Patients | 5-year PFS | 5-year OS | |||||
---|---|---|---|---|---|---|---|---|
# | % | % | SE | Log-rank (p) | % | SE | Log-rank (p) | |
Age >3 years | ||||||||
Yes | 25 | 69 | 51 | 12 | 0.36 | 46 | 15 | 0.36 |
No | 11 | 31 | 18 | 16 | 36 | 21 | ||
Sex | ||||||||
Male | 26 | 72 | 44 | 13 | 0.30 | 45 | 16 | 0.20 |
Female | 10 | 28 | 35 | 16 | 42 | 17 | ||
Tumor location | ||||||||
Supratentorial | 13 | 36 | 32 | 16 | 0.16 | 45 | 21 | 0.97 |
Infratentorial | 23 | 64 | 46 | 13 | 42 | 16 | ||
Grade | ||||||||
2 | 14 | 39 | 42 | 17 | 0.45 | 69 | 19 | 0.02* |
3 | 22 | 61 | 41 | 12 | 25 | 14 | ||
Resection | ||||||||
GTR | 21 | 58 | 49 | 14 | 0.35 | 54 | 17 | 0.07 |
Subtotal | 13 | 36 | 31 | 15 | 33 | 18 | ||
Biopsy | 2 | 6 | 50 | 35 | 50 | 35 | ||
Radiation | ||||||||
Yes | 25 | 69 | 51 | 12 | 0.03* | 53 | 16 | 0.03* |
No | 11 | 31 | 20 | 16 | 21 | 17 | ||
Chemotherapy | ||||||||
Yes | 21 | 58 | 40 | 14 | 0.94 | 45 | 16 | 0.75 |
No | 15 | 42 | 43 | 15 | 41 | 20 | ||
Telomerase activity | ||||||||
Yes | 23 | 64 | 29 | 11 | 0.03* | 58 | 12 | 0.05* |
No | 13 | 36 | 64 | 18 | 83 | 15 |
PFS Progression-free survival, OS overall survival, SE standard error, GTR gross total resection
* Significance as determined by log-rank statistics at p ≤ 0.05